H.C. Wainwright analyst Arthur He initiated coverage of Nektar (NKTR) with a Buy rating and $6.50 price target Nektar is a clinical-stage biopharmaceutical company focused on developing innovative medicines that selectively modulate the immune system to address autoimmune diseases with its “deep knowledge and expertise” in immunology and polymer chemistry, the analyst tells investors in a research note. The firm believes Nektar’s lead drug rezpegaldesleukin is a potential best-in-class Treg agonist that could restore immune homeostasis for the treatment of a variety of autoimmune disorders. It currently projects the company to generate risk-adjusted revenues of $947M in 2035, growing from $85M in 2029.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NKTR:
- Nektar presents preclinical data on NKTR-422 at ACR conference
- Nektar Therapeutics Reports Stable Q3 Earnings for 2024
- Nektar reports Q3 EPS (18c), consensus (20c)
- Biotech Alert: Searches spiking for these stocks today
- Nektar presents late-breaking results from Phase 2 Study of NKTR-255
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
